MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
27.15
+0.47
+1.76%
After Hours: 27.17 +0.02 +0.07% 18:16 12/12 EST
OPEN
26.75
PREV CLOSE
26.68
HIGH
27.28
LOW
26.42
VOLUME
1.40M
TURNOVER
--
52 WEEK HIGH
27.73
52 WEEK LOW
13.40
MARKET CAP
4.59B
P/E (TTM)
17.49
1D
5D
1M
3M
1Y
5Y
1D
FDA Approves Acadia's DAYBUE STIX Powder For Oral Solution For Rett Syndrome
NASDAQ · 1d ago
FDA Approves Acadia's Powder Formulation Of DAYBUE For Rett Syndrome
NASDAQ · 1d ago
BRIEF-Acadia Pharmaceuticals Announces FDA Approval Of DAYBUE STIX For Oral Solution, A New Powder Formulation Of Trofinetide For The Treatment Of Rett Syndrome
Reuters · 1d ago
FDA Approves Acadia Pharmaceuticals' DAYBUE STIX for Rett Syndrome
Reuters · 1d ago
ACADIA Pharmaceuticals Is Maintained at Hold by Stifel
Dow Jones · 2d ago
Stifel Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $25
Benzinga · 2d ago
ACADIA Pharmaceuticals (ACAD) Receives a Hold from Stifel Nicolaus
TipRanks · 2d ago
Acadia Pharmaceuticals price target raised to $25 from $24 at Stifel
TipRanks · 2d ago
More
About ACAD
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. It develops and commercializes medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of product candidates and research programs that are designed to address significant unmet medical needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and ACP-711. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. Its early-stage research programs and product candidates include ACP-211, ACP-2591, ACP-271, and Antisense Oligonucleotide (ASO) Programs.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.